Epolix

Epolix is a recombinant erythropoietin alpha biosimilar developed by Opal Bio Pharma for the management of anemia. It functions as an erythropoietin receptor agonist, stimulating the bone marrow to produce red blood cells, thereby mimicking the effect of natural erythropoietin. The product is primarily indicated for anemia resulting from chronic kidney disease (CKD), chemotherapy-induced anemia, and anemia associated with HIV. It is available in pre-filled syringe formats (2000 IU and 4000 IU) and is marketed as a cost-effective alternative to established reference brands like Epogen and Procrit. Epolix has received regulatory approvals in several regions, including the European Union and Gulf Cooperation Council (GCC) countries.

Brand names

Epolix

Other names

biosimilar erythropoietinerythropoietin alpha biosimilarEpolix-Opal Bio Pharma